GEORGETOWN, Texas (PRWEB) October 30, 2018
Dr. Loubert S. Suddaby, a neurosurgeon practicing in Buffalo, New York, attended NASS 2018 and provided educational training to physicians and company personnel about his experience with ORTHOReBIRTH USA's ReBOSSIS®, the only biosynthetic scaffold with electrospun microfiber construction.
“Dr. Suddaby’s has had a great deal of success with ReBOSSIS,” says Doris Blake, president and COO of ORTHOReBIRTH USA. “We are thrilled that he is sharing information with his peers, and we hope that others in this field realize the superior outcomes offered by this biologic.”
Last year, the Food and Drug Administration cleared ReBOSSIS for use in posterolateral spine procedures, and tests performed at the Cleveland Clinic Lerner Research Institute and at the Orthopaedic Stem Cell Research Laboratory at Cedars-Sinai further validated the fact that ReBOSSIS supports cell activation, retention, and proliferation.
“We have been pleased with ReBOSSIS’ results,” says Blake, “and having this product at an event put on by The North American Spine Society is monumental. We are anxious to see what’s next.”
About ORTHOReBIRTH USA
We recognize the challenges associated with orthopedic surgery—for patients, surgeons and hospitals alike. We are committed to bringing to market cutting-edge orthopedic biologics that improve patients’ quality of life and offer superior outcomes. We have carried out extensive studies on what makes biologic materials successful and have used that knowledge to engineer world-class products for use in a host of orthopedic surgical procedures. ORTHOReBIRTH USA is proud to bring premium orthopedic biologics, such as ReBOSSIS®, to surgeons practicing around the world.